Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to $800

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and lowers the price target from $825 to $800.